SML BIOPHARM
SML Biopharm Co., Ltd. is an innovative company leading the research and development of mRNA vaccines and therapeutics. Established in 2021, SML Biopharm is developing next-generation cancer vaccines and various disease treatments by combining cutting-edge mRNA platforms with advanced LNP drug delivery systems, leveraging mRNA technology that gained significant attention through COVID-19.
Core technologies
Our linear mRNA platform optimizes 3’ UTR and poly(A) tail to enhance mRNA stability and protein expression, making it ideal for vaccines and therapeutics.
SML Biopharm is developing new drug pipelines using immune and protein expression approaches and advancing a next-generation mRNA platform for better stability and effectiveness. We also independently synthesize and develop lipid nanoparticles (LNPs) for efficient mRNA delivery. With our innovative mRNA and LNP technologies, we drive effective R&D and rapid achievements.
Personalized cancer vaccine
Traditional cancer treatments typically involve administering the same type of therapy to all patients regardless of their unique biomarkers, resulting in varying levels of effectiveness. However, personalized cancer vaccines represent a significant advancement. By analyzing the tumour specific neoantigen information from each patient and delivering it, these vaccines offer tailored treatments, thereby enhancing their effectiveness for each individual.
SML’s cancer vaccine
SML Biopharm is developing various cancer vaccines using our core technology. Our cancer vaccines work by delivering information about cancer-causing antigens to the body via mRNA-LNP, enabling the immune system to recognize and eliminate these antigens. Currently, SML Biopharm is developing therapeutic vaccines for cervical cancer caused by infection of human papillomavirus (HPV) and has shown effective anti-cancer efficacy in mice.
Additionally, SML Biopharm is conducting research on next-generation personalized cancer vaccines. We analyzed the genes of healthy mice and mice with colon cancer to predict neoantigens, then administered a vaccine using our mRNA-LNP technology to the cancer affected mice, resulting in effective anti-cancer efficacy. Moving forward, we plan to develop personalized cancer vaccines for human patients. Additionally, we aim to expand the application of our mRNA-LNP technology to treat various diseases, including rare diseases. Through these efforts, we are committed to working towards a healthier future for people.
- For more information, visit: www.smlbiopharm.com
